BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Save up to 60%* for Ultimate Trader

1 year 40%, 2 years 50% and *3 years 60%

*Across 3 years $3395.52 only $1358.21

ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      6,021.63
      0.57%
      US Tech 100
      20,302.00
      -0.35%
      Dow Jones
      44,860.31
      0.28%
      Brent Oil
      72.65
      0.28%
      Bitcoin
      93,453.06
      1.61%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Dianthus Therapeutics Inc (DNTH) Quote

      Dianthus Therapeutics Inc

      Dianthus Therapeutics Inc (DNTH)

      NASDAQ
      23.86
      0.41
      (1.75%)
      Closed November 26 4:00PM
      Delayed by 15 minutes
      23.86
      0.00
      ( 0.00% )
      Pre Market: 6:10AM
      Delayed by 15 minutes

      Professional-Grade Tools, for Individual Investors.

      Premium

      Key stats and details

      Current Price
      23.86
      Bid
      9.55
      Ask
      23.31
      Volume
      200
      0.00 Day's Range 0.00
      6.58 52 Week Range 33.77
      Market Cap
      706.184M
      Previous Close
      23.86
      Open
      -
      Last Trade
      95
      @
      22.3
      Last Trade Time
      05:56:39
      Financial Volume
      -
      VWAP
      -
      Average Volume (3m)
      251,574
      Shares Outstanding
      29,596,965
      Dividend Yield
      -
      PE Ratio
      -16.21
      Earnings Per Share (EPS)
      -1.47
      Revenue
      2.83M
      Net Profit
      -43.56M

      About Dianthus Therapeutics Inc

      Magenta Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy. The pipeline of the company includes MGTA-117, MGTA-145, and others. Magenta Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy. The pipeline of the company includes MGTA-117, MGTA-145, and others.

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.magentatx.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -
      Dianthus Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker DNTH. The last closing price for Dianthus Therapeutics was $23.86. Over the last year, Dianthus Therapeutics shares have traded in a share price range of $ 6.58 to $ 33.77.

      Dianthus Therapeutics currently has 29,596,965 shares outstanding. The market capitalization of Dianthus Therapeutics is $706.18 million. Dianthus Therapeutics has a price to earnings ratio (PE ratio) of -16.21.

      Ask ADVFN Intelligence (AI)

      DNTH Latest News

      More News

      FeaturedCannabix Technologies Receives Positive Testing Certification for Breath Logix Autonomous Alcohol Breathalyzer

      22 hours ago

      FeaturedBioQuest, Inc. and BotMakers Expand AI Marketing Services with SpeedLeads XL and MarketScope XL. Bioquest Corp. and BotMakers, Inc. are Partnered to Expand AI Marketing Services with SpeedLead XL and MarketScope XL

      23 hours ago

      Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results

      Initiation of a single, two-part, pivotal Phase 3 trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) anticipated by YE’24 Phase 2 MaGic trial of DNTH103 in generalized...

      November 07 2024
      GlobeNewswire Inc.

      Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences

      NEW YORK and WALTHAM, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of...

      November 04 2024
      GlobeNewswire Inc.

      Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting

      NEW YORK and WALTHAM, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of...

      October 15 2024
      GlobeNewswire Inc.

      Dianthus Therapeutics to Participate in Three Healthcare Investor Conferences in September

      NEW YORK and WALTHAM, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of...

      September 04 2024
      GlobeNewswire Inc.

      Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results

      Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) ongoing; top-line results anticipated in 2H’25 IND for Phase 2 MoMeNtum trial in Multifocal Motor Neuropathy (MMN) cleared by FDA in...

      August 08 2024
      GlobeNewswire Inc.

      Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN)

      NEW YORK and WALTHAM, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of...

      June 28 2024
      GlobeNewswire Inc.

      Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy (MMN)

      Top-line results from Phase 2 MoMeNtum trial in Multifocal Motor Neuropathy anticipated in 2H 2026 Building a neuromuscular franchise with DNTH103 following the initiation of the Phase 2 MaGic...

      June 12 2024
      GlobeNewswire Inc.

      Dianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference

      NEW YORK and WALTHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of...

      May 30 2024
      GlobeNewswire Inc.
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      11.647.3807380738122.2224.29519.84525472222.12546327CS
      4-3.765-13.62895927627.62531.9719.84532405125.37955948CS
      12-3.8-13.738250180827.6631.9719.84525157426.6377394CS
      261.25.2956751985922.6631.9719.84525702126.52983359CS
      5212.6111.9005328611.2633.776.5818854725.59642116CS
      15613.46129.42307692310.433.776.5816007325.25460085CS
      26013.46129.42307692310.433.776.5816007325.25460085CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      HWHHWH International Inc
      $ 1.08
      (91.15%)
      		7.71M
      CYCNCyclerion Therapeutics Inc
      $ 2.28
      (67.65%)
      		8.03M
      IFBDInfobird Company Ltd
      $ 2.79
      (53.30%)
      		4.1M
      IDAIT Stamp Inc
      $ 0.513
      (40.55%)
      		11.24M
      QMCOQuantum Corporation
      $ 22.14
      (28.50%)
      		467.78k
      PGHLPrimega Group Holdings Ltd
      $ 12.69
      (-88.18%)
      		265.6k
      WAVEEco Wave Power Global AB
      $ 6.50
      (-44.01%)
      		2
      IMGCIMG Inc
      $ 1.17
      (-26.88%)
      		357.38k
      SDOTSadot Group Inc
      $ 3.01
      (-24.75%)
      		674
      LEGHLegacy Housing Corporation
      $ 20.00
      (-22.78%)
      		106
      IDAIT Stamp Inc
      $ 0.513
      (40.55%)
      		11.24M
      CYCNCyclerion Therapeutics Inc
      $ 2.28
      (67.65%)
      		8.03M
      HWHHWH International Inc
      $ 1.08
      (91.15%)
      		7.71M
      DUOFangDD Network Group Ltd
      $ 0.5845
      (9.87%)
      		5.36M
      RGTIRigetti Computing Inc
      $ 2.46
      (11.82%)
      		4.63M

      DNTH Discussion

      View Posts
      Monksdream Monksdream 2 months ago
      DNTH moving sideways
      👍️0
      Monksdream Monksdream 8 months ago
      DNTH new 52 hi
      👍️0

      Your Recent History

      NASDAQ
      DNTH
      Dianthus Therapeutics
      NASDAQ
      VIRC
      Virco Manufacturing
      BIT
      GHC
      Garofalo Health Care
      USOTC
      GVDNY
      Givaudan (PK)
      Delayed Upgrade Clock